Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 11,650
+390 (3.46%)
At close: Feb 6, 2026
Prestige BioPharma Revenue
Prestige BioPharma had revenue of 2.31B KRW in the quarter ending September 30, 2025, with 3.87% growth. This brings the company's revenue in the last twelve months to 14.41B, up 406.89% year-over-year. In the fiscal year ending June 30, 2025, Prestige BioPharma had annual revenue of 14.33B with 1,978.97% growth.
Revenue (ttm)
14.41B
Revenue Growth
+406.89%
P/S Ratio
9.72
Revenue / Employee
n/a
Employees
n/a
Market Cap
140.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 14.33B | 13.64B | 1,978.97% |
| Jun 30, 2024 | 689.08M | 527.23M | 325.77% |
| Jun 30, 2023 | 161.84M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Macrogen | 179.98B |
| Amicogen | 87.97B |
| HLB Therapeutics | 63.25B |
| GeneOne Life Science | 30.90B |
| CG Invites | 18.12B |
| ENCell | 5.91B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.56B |